Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.

Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R, Bouvier N, Vakiani E, Gao J, Heins ZJ, Gross BE, Kelsen DP, Zhang L, Strong VE, Schattner M, Gerdes H, Coit DG, Bains M, Stadler ZK, Rusch VW, Jones DR, Molena D, Shia J, Robson ME, Capanu M, Middha S, Zehir A, Hyman DM, Scaltriti M, Ladanyi M, Rosen N, Ilson DH, Berger MF, Tang L, Taylor BS, Solit DB, Schultz N.

Cancer Discov. 2018 Jan;8(1):49-58. doi: 10.1158/2159-8290.CD-17-0787. Epub 2017 Nov 9.

2.

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV.

Cancer Discov. 2018 Jan;8(1):37-48. doi: 10.1158/2159-8290.CD-17-0395. Epub 2017 Oct 4.

3.

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY.

Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.

PMID:
30463996
4.

Immunotherapy for Esophageal and Gastric Cancer.

Kelly RJ.

Am Soc Clin Oncol Educ Book. 2017;37:292-300. doi: 10.14694/EDBK_175231. Review.

5.

Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E.

BMC Cancer. 2011 Oct 20;11:455. doi: 10.1186/1471-2407-11-455.

6.

What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?

De Mello RA, Castelo-Branco L, Castelo-Branco P, Pozza DH, Vermeulen L, Palacio S, Salzberg M, Lockhart AC.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:249-261. doi: 10.1200/EDBK_198805. Review.

PMID:
30231398
7.

Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.

Kim J, Fox C, Peng S, Pusung M, Pectasides E, Matthee E, Hong YS, Do IG, Jang J, Thorner AR, Van Hummelen P, Rustgi AK, Wong KK, Zhou Z, Tang P, Kim KM, Lee J, Bass AJ.

J Clin Invest. 2014 Dec;124(12):5145-58. doi: 10.1172/JCI75200. Epub 2014 Nov 17.

8.

Clinical impact of tumour biology in the management of gastroesophageal cancer.

Lordick F, Janjigian YY.

Nat Rev Clin Oncol. 2016 Jun;13(6):348-60. doi: 10.1038/nrclinonc.2016.15. Epub 2016 Mar 1. Review.

9.

Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.

Lin EM, Gong J, Klempner SJ, Chao J.

World J Gastroenterol. 2018 Jul 7;24(25):2686-2697. doi: 10.3748/wjg.v24.i25.2686. Review.

10.

Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.

Apicella M, Migliore C, Capelôa T, Menegon S, Cargnelutti M, Degiuli M, Sapino A, Sottile A, Sarotto I, Casorzo L, Cassoni P, De Simone M, Comoglio PM, Marsoni S, Corso S, Giordano S.

Oncogene. 2017 Mar 2;36(9):1200-1210. doi: 10.1038/onc.2016.283. Epub 2016 Aug 15.

PMID:
27524418
11.

Impact of genetic targets on cancer therapy in esophagogastric cancer.

Jiang Y.

Adv Exp Med Biol. 2013;779:55-65. doi: 10.1007/978-1-4614-6176-0_3. Review.

PMID:
23288635
12.

Perspectives of HER2-targeting in gastric and esophageal cancer.

Gerson JN, Skariah S, Denlinger CS, Astsaturov I.

Expert Opin Investig Drugs. 2017 May;26(5):531-540. doi: 10.1080/13543784.2017.1315406. Review.

13.

Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.

Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Borger DR, Godfrey JT, Jessop NA, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A, Hong TS, Corcoran RB.

Cancer Discov. 2015 Dec;5(12):1271-81. doi: 10.1158/2159-8290.CD-15-0748. Epub 2015 Oct 2. Erratum in: Cancer Discov. 2016 Dec;6(12 ):1402.

14.

Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.

Bain GH, Collie-Duguid E, Murray GI, Gilbert FJ, Denison A, McKiddie F, Ahearn T, Fleming I, Leeds J, Phull P, Park K, Nanthakumaran S, Matula KM, Grabsch HI, Tan P, Welch A, Schweiger L, Dahle-Smith A, Urquhart G, Finegan M, Petty RD.

Br J Cancer. 2014 Mar 18;110(6):1525-34. doi: 10.1038/bjc.2014.45. Epub 2014 Feb 25. Erratum in: Br J Cancer. 2015 Dec 1;113(11):1641. Matula, K M [added].

15.

Genomic Profiling of Small-Bowel Adenocarcinoma.

Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, Ross JS, Wilson R, Miller VA, Ali SM, Overman MJ.

JAMA Oncol. 2017 Nov 1;3(11):1546-1553. doi: 10.1001/jamaoncol.2017.1051.

16.

Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer.

Bolm L, Käsmann L, Paysen A, Karapetis C, Rades D, Wellner UF, Keck T, Watson DI, Hummel R, Hussey DJ.

Anticancer Res. 2018 Jun;38(6):3231-3242. doi: 10.21873/anticanres.12588. Review.

PMID:
29848670
17.
18.

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.

Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, Novotny A, Pauligk C, Homann N, Jungbluth T, Reissfelder C, Caca K, Retter S, Horndasch E, Gumpp J, Bolling C, Fuchs KH, Blau W, Padberg W, Pohl M, Wunsch A, Michl P, Mannes F, Schwarzbach M, Schmalenberg H, Hohaus M, Scholz C, Benckert C, Knorrenschild JR, Kanngießer V, Zander T, Alakus H, Hofheinz RD, Roedel C, Shah MA, Sasako M, Lorenz D, Izbicki J, Bechstein WO, Lang H, Moenig SP.

BMC Cancer. 2017 Dec 28;17(1):893. doi: 10.1186/s12885-017-3918-9.

19.

The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.

Saunders JH, Bowman CR, Reece-Smith AM, Pang V, Dorrington MS, Mumtaz E, Soomro I, Kaye P, Madhusudan S, Parsons SL.

J Surg Oncol. 2017 Jun;115(7):821-829. doi: 10.1002/jso.24601. Epub 2017 Mar 2.

PMID:
28257148
20.

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY, Lenz HJ, Press MF.

Ann Oncol. 2013 Jul;24(7):1754-61. doi: 10.1093/annonc/mdt106. Epub 2013 Mar 22.

Supplemental Content

Support Center